INC Research Becomes First CRO to Achieve Accreditations Across Entire Medidata Clinical Cloud
(Thomson Reuters ONE) -
Achievement further reinforces Company's focus on innovation
to deliver more efficient clinical development solutions
Raleigh, N.C., June 24, 2013 - INC Research LLC, a therapeutically focused
global clinical research organization (CRO) with a Trusted Process® for
delivering reliable results, today announced it has attained four new
accreditations in the Medidata Clinical Cloud(TM), further reinforcing its
focus on innovation to help biopharmaceutical companies overcome critical cost,
risk and efficiency challenges across the clinical chain. With new
accreditations in Medidata Designer(®), Medidata Grants Manager(®), Medidata
CTMS(TM) and Medidata Rave(®) Safety Gateway, INC Research becomes the most
highly accredited Medidata Services Partner and the first Company to achieve all
available accreditations in the Medidata platform.
"INC Research's therapeutic focus and process expertise along with Medidata's
innovative cloud-based clinical research platform provide a winning combination
to streamline clinical development for our biopharmaceutical customers," said
Alistair Macdonald, Chief Operating Officer. "By leveraging Medidata's cloud-
based clinical research platform along with our own Trusted Process®
methodology, INC can deliver time and cost-efficient methods that accelerate
clinical development and optimize trials of every scope and scale from protocol
design all the way through to database lock."
With accreditation in Medidata Designer, INC Research is combining its long-
standing therapeutic expertise and commitment to operational excellence with
leading-edge technologies to ensure each protocol is as focused and streamlined
as possible to drive efficiencies and reduce associated drug development costs.
By leveraging Medidata's Grants Manager and CTMS applications, the Company is
able to deliver more efficient site payments and monitoring visit reporting,
while offering increased visibility into trial milestones. Using the Medidata
Rave Safety Gateway, INC Research can now automate sponsors' EDC-to-safety-
system data transfers to expedite case triage, improving the accuracy of serious
adverse event (SAE) case data and reducing data reconciliation activities to
eliminate error-prone phone, paper and fax processes.
"As one of the first CROs to join the Medidata Partner Program, INC Research's
extraordinary familiarity and expertise is well known when it comes to
leveraging the Medidata platform," said Steve Heath, Vice President of Channel
Sales at Medidata Solutions. "By becoming one of the first partners to achieve
accreditations for Medidata CTMS, Grants Manager and Rave Safety Gateway and the
first CRO to become accredited in Medidata's platform for all currently
available accreditations, INC Research demonstrates once again why it is a
leader in applying its clinical expertise and capabilities with best-in-class
cloud-based technologies."
In 2006, INC Research became one of the first CROs to join the Medidata Partner
Program. The Company achieved its first Medidata accreditation in 2007 for
Medidata Rave, an electronic data capture (EDC) and clinical data management
(CDM) system, and since that time has conducted more than 160 study-builds using
this tool. In May 2012, INC attained three additional accreditations, including
Medidata Balance(TM), RaveTargeted SDV and Medidata Coder(®). With its four
newest accreditations, INC Research holds more accreditations than any other
Medidata Services Partner.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to us
for a complete range of customized Phase I to IV programs in all therapeutic
areas and patient populations. Our Trusted Process® methodology and therapeutic
foresight lead customers to better-informed product development decisions, while
our solid site relationships are a critical success factor in delivering
clinical trial results on time and on budget. INC was ranked "Top CRO" by sites
worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey.
INC Research is headquartered in Raleigh, NC. For more information, please
visit www.incresearch.com or follow us at (at)inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
About Medidata Solutions
Medidata Solutions is the leading global provider of cloud-based solutions for
clinical research in life sciences, transforming clinical development through
its advanced applications and intelligent data analytics. The Medidata Clinical
Cloud(TM) brings new levels of productivity and quality to the clinical testing
of promising medical treatments, from study design and planning through
execution, management and reporting. We are committed to advancing the
competitive and scientific goals of global customers, which include over 90% of
the top 25 global pharmaceutical companies; innovative biotech, diagnostic and
device firms; leading academic medical centers; and contract research
organizations. For more information, please visit www.mdsol.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1711269]
Unternehmensinformation / Kurzprofil:
Datum: 24.06.2013 - 14:01 Uhr
Sprache: Deutsch
News-ID 272528
Anzahl Zeichen: 6251
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 123 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Becomes First CRO to Achieve Accreditations Across Entire Medidata Clinical Cloud"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
